Exact Mass: 819.6529099999999
Exact Mass Matches: 819.6529099999999
Found 439 metabolites which its exact mass value is equals to given mass value 819.6529099999999,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
2,3-Bis-(O-phytanyl)-sn-glycero-1-phospho-L-serine
C46H94NO8P (819.6716693999999)
PC(O-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z))
PC(O-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(O-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of Stearyl alcohol at the C-1 position and one chain of docosahexaenoic acid at the C-2 position. The Stearyl alcohol moiety is derived from beef fat, fish oil, while the docosahexaenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. PC(o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(o-18:0/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of Stearyl alcohol at the C-1 position and one chain of docosahexaenoic acid at the C-2 position. The Stearyl alcohol moiety is derived from beef fat, fish oil, while the docosahexaenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(11Z))
PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(11Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(11Z)), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The adrenic acid moiety is derived from animal fats, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(9Z))
PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(9Z)), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The adrenic acid moiety is derived from animal fats, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(9Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:4(7Z,10Z,13Z,16Z)/P-18:1(9Z)), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The adrenic acid moiety is derived from animal fats, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:0)
PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:0), in particular, consists of one chain of docosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The docosapentaenoic acid moiety is derived from animal fats and brain, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:5(4Z,7Z,10Z,13Z,16Z)/P-18:0), in particular, consists of one chain of docosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The docosapentaenoic acid moiety is derived from animal fats and brain, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:0)
PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:0) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(22:5(7Z,10Z,13Z,16Z,19Z)/P-18:0), in particular, consists of one chain of docosapentaenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The docosapentaenoic acid moiety is derived from fish oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:0/22:5(4Z,7Z,10Z,13Z,16Z))
PC(P-18:0/22:5(4Z,7Z,10Z,13Z,16Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of docosapentaenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the docosapentaenoic acid moiety is derived from animal fats and brain. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:0/22:5(4Z,7Z,10Z,13Z,16Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of docosapentaenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the docosapentaenoic acid moiety is derived from animal fats and brain. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:0/22:5(7Z,10Z,13Z,16Z,19Z))
PC(P-18:0/22:5(7Z,10Z,13Z,16Z,19Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:0/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of docosapentaenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the docosapentaenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(P-18:1(11Z)/22:4(7Z,10Z,13Z,16Z))
PC(P-18:1(11Z)/22:4(7Z,10Z,13Z,16Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of adrenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the adrenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PC(P-18:1(11Z)/22:4(7Z,10Z,13Z,16Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(11Z)/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of adrenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the adrenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PC(P-18:1(9Z)/22:4(7Z,10Z,13Z,16Z))
PC(P-18:1(9Z)/22:4(7Z,10Z,13Z,16Z)) is a phosphatidylcholine (PC or GPCho). It is a glycerophospholipid in which a phosphorylcholine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PC(P-18:1(9Z)/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of adrenic acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the adrenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PCs can be synthesized via three different routes. In one route, choline is activated first by phosphorylation and then by coupling to CDP prior to attachment to phosphatidic acid. PCs can also synthesized by the addition of choline to CDP-activated 1,2-diacylglycerol. A third route to PC synthesis involves the conversion of either PS or PE to PC. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PC(O-18:0/22:6)
PC(O-18:0/22:6)[U]
PC(P-20:0/20:5(5Z,8Z,11Z,14Z,17Z))
2,3-bis-O-phytanyl-sn-glycero-3-phospho-L-serine
C46H94NO8P (819.6716693999999)
2-[[(2S,3R)-2-[7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]heptanoylamino]-3-hydroxynonadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(2S,3S,4R)-3,4-dihydroxy-15-methyl-2-(tetracosanoylamino)hexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
[3-dodecoxy-2-[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[3-nonanoyloxy-2-[(16Z,19Z,22Z)-triaconta-16,19,22-trienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-[(Z)-icos-11-enoyl]oxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-[(Z)-docos-13-enoyl]oxy-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-pentadecanoyloxy-2-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-[(Z)-heptadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]oxy-3-undecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-[(Z)-henicos-11-enoyl]oxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-[(Z)-nonadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-tricosanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-[(Z)-pentadec-9-enoyl]oxy-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxy-3-nonadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-heptadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]oxy-3-tridecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-henicosanoyloxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
(9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(4E,8E,12E)-1,3-dihydroxytetradeca-4,8,12-trien-2-yl]dotetraconta-9,12,15,18,21,24,27,30,33,36,39-undecaenamide
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]dotetraconta-6,9,12,15,18,21,24,27,30,33,36,39-dodecaenamide
(7Z,10Z,13Z,16Z,19Z,22Z,25Z,28Z,31Z,34Z,37Z)-N-[(4E,8E,12E)-1,3-dihydroxyhexadeca-4,8,12-trien-2-yl]tetraconta-7,10,13,16,19,22,25,28,31,34,37-undecaenamide
(8Z,11Z,14Z,17Z,20Z,23Z,26Z,29Z,32Z,35Z,38Z,41Z)-N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tetratetraconta-8,11,14,17,20,23,26,29,32,35,38,41-dodecaenamide
[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-octadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]tricosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]pentacosa-4,8,12-triene-1-sulfonic acid
2-Amino-3-[(2-henicosanoyloxy-3-octadecoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(3-icosoxy-2-nonadecanoyloxypropoxy)phosphoryl]oxypropanoic acid
(E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]hexacos-4-ene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-henicosoxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate
3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]hexacosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]propan-2-yl] heptadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] (6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoate
2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxytetracosane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate
(E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxytetracos-4-ene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] (Z)-nonadec-9-enoate
(4E,8E,12E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoxy]propan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] (14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoxy]propan-2-yl] (Z)-pentadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propan-2-yl] nonadecanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoate
(4E,8E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]hexacosa-4,8-diene-1-sulfonic acid
(4E,8E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxytetracosa-4,8-diene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]propan-2-yl] (Z)-heptadec-9-enoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-henicos-11-enoxy]propan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] (10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoxy]propan-2-yl] pentadecanoate
(4E,8E,12E)-2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxytetracosa-4,8,12-triene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
[2-hexadecanoyloxy-3-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[(3-docosoxy-2-heptadecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
[3-[(11Z,14Z)-icosa-11,14-dienoxy]-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-hexadecoxy-2-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoxy]-2-tetradecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[(3-hexadecoxy-2-tricosanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
[2-dodecanoyloxy-3-[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[hydroxy-(2-pentacosanoyloxy-3-tetradecoxypropoxy)phosphoryl]oxypropanoic acid
[3-[(13Z,16Z)-docosa-13,16-dienoxy]-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-2-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[(2-hexadecanoyloxy-3-tricosoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(2-icosanoyloxy-3-nonadecoxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(2-hexacosanoyloxy-3-tridecoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
[2-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]oxy-3-[(Z)-tetradec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(13Z,16Z)-tetracosa-13,16-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(Z)-hexadec-9-enoyl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(Z)-hexadec-9-enoxy]-2-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]-2-[(Z)-tetradec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[hydroxy-(3-pentadecoxy-2-tetracosanoyloxypropoxy)phosphoryl]oxypropanoic acid
[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(Z)-icos-11-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[(3-henicosoxy-2-octadecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
[2-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxy-3-tetradecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-Amino-3-[hydroxy-(2-pentadecanoyloxy-3-tetracosoxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(3-hexacosoxy-2-tridecanoyloxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
2-Amino-3-[hydroxy-(3-pentacosoxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropanoic acid
2-Amino-3-[(2-docosanoyloxy-3-heptadecoxypropoxy)-hydroxyphosphoryl]oxypropanoic acid
[3-[(Z)-docos-13-enoxy]-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-[4-[3-[(Z)-docos-13-enoyl]oxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]ethanesulfonic acid
2-[4-[3-[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]oxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
2-[4-(10,13-dimethyl-3-tricosanoyloxy-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]ethanesulfonic acid
4-[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-tetracosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-nonadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-henicosanoyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-henicos-11-enoyl]oxy-3-[(Z)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-icosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-docosanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-docos-13-enoyl]oxy-3-[(Z)-octadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(Z)-tetracos-13-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-hexadecanoyloxy-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2,3-bis[[(Z)-icos-11-enoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(Z)-hexacos-15-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-2-[(Z)-icos-11-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]-2-[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(9Z,12Z)-hexadeca-9,12-dienoxy]-2-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(Z)-docos-13-enoyl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]-2-octadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-2-[(Z)-octadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] (Z)-henicos-11-enoate
[3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate
[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(Z)-octadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoxy]propan-2-yl] henicosanoate
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytriaconta-4,8,12-trien-2-yl]tridec-8-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosa-4,8,12-trien-2-yl]docos-11-enamide
(4Z,7Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptacosa-4,8-dien-2-yl]hexadeca-4,7-dienamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptacosa-4,8,12-trien-2-yl]hexadec-7-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8,12-trien-2-yl]nonacos-14-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8,12-trien-2-yl]tricos-11-enamide
(10Z,12Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacosa-4,8-dien-2-yl]octadeca-10,12-dienamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacosa-4,8,12-trien-2-yl]octadec-11-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosa-4,8,12-trien-2-yl]henicos-9-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8,12-trien-2-yl]octacos-13-enamide
(14Z,16Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosa-4,8-dien-2-yl]docosa-14,16-dienamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8,12-trien-2-yl]hexacos-11-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadeca-4,8,12-trien-2-yl]tetracos-11-enamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8,12-trien-2-yl]heptacos-12-enamide
(18Z,21Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadeca-4,8-dien-2-yl]tetracosa-18,21-dienamide
(13Z,16Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8-dien-2-yl]octacosa-13,16-dienamide
(Z)-N-[(4E,8E,12E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8,12-trien-2-yl]pentacos-11-enamide
(11Z,14Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8-dien-2-yl]hexacosa-11,14-dienamide
(5E,8E,11E,14E)-N-[(2S,3R)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadecan-2-yl]tetracosa-5,8,11,14-tetraenamide
4-[3-[(9E,11E)-henicosa-9,11-dienoyl]oxy-2-nonadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-hexadec-7-enoyl]oxy-2-[(E)-tetracos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-henicosanoyloxy-2-[(7E,9E)-nonadeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(11E,14E)-hexacosa-11,14-dienoyl]oxy-2-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-docos-11-enoyl]oxy-2-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-2-[(4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoyl]oxy-3-[(E)-octadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
4-[3-[(14E,16E)-docosa-14,16-dienoyl]oxy-2-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-henicosanoyloxy-3-[(7E,9E)-nonadeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(11E,14E)-pentacosa-11,14-dienoyl]oxy-2-pentadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-hexacos-11-enoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-docos-11-enoyl]oxy-3-[(E)-octadec-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,14E)-icosa-11,14-dienoyl]oxy-3-icosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(2S,3R,4E,8E)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
4-[2-[(E)-hexadec-7-enoyl]oxy-3-[(E)-tetracos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-2-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-docosanoyloxy-3-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-heptadec-7-enoyl]oxy-3-[(E)-tricos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-heptadecanoyloxy-3-[(14E,16E)-tricosa-14,16-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-hexadecanoyloxy-3-[(18E,21E)-tetracosa-18,21-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-pentacosanoyloxy-2-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(11E,14E)-icosa-11,14-dienoyl]oxy-2-icosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-tetracosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-pentacos-11-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(E)-octadec-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
4-[2-[(E)-henicos-9-enoyl]oxy-3-[(E)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-docosanoyloxy-2-[(10E,12E)-octadeca-10,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-heptadec-7-enoyl]oxy-2-[(E)-tricos-11-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-pentacosanoyloxy-3-[(9E,12E)-pentadeca-9,12-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-tetracosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-henicos-9-enoyl]oxy-2-[(E)-nonadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,14E)-pentacosa-11,14-dienoyl]oxy-3-pentadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(E)-pentacos-11-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-hexadecanoyloxy-2-[(18E,21E)-tetracosa-18,21-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(14E,16E)-docosa-14,16-dienoyl]oxy-3-octadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-heptadecanoyloxy-2-[(14E,16E)-tricosa-14,16-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,14E)-heptadeca-11,14-dienoyl]oxy-3-tricosanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E)-henicosa-9,11-dienoyl]oxy-3-nonadecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-hexacosanoyloxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-hexacos-11-enoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(E)-icos-1-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
4-[2,3-bis[[(E)-icos-11-enoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(11E,14E)-hexacosa-11,14-dienoyl]oxy-3-tetradecanoyloxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-hexacosanoyloxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]nonadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]pentacosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(18Z,21Z,24Z,27Z)-triaconta-18,21,24,27-tetraenoyl]amino]trideca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(4E,8E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxyheptacosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(4E,8E,12E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxyheptadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[3-hydroxy-2-[[(16Z,19Z,22Z,25Z,28Z,31Z)-tetratriaconta-16,19,22,25,28,31-hexaenoyl]amino]nonoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[3-hydroxy-2-[[(10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-10,13,16,19,22,25-hexaenoyl]amino]pentadecoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(14Z,17Z,20Z)-octacosa-14,17,20-trienoyl]amino]pentadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(4E,8E,12E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxyheptacosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(E)-2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxyhenicos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoyl]amino]pentadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]tricosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[3,4-Dihydroxy-2-(tricosanoylamino)octadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]nonadecoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]tricos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]tricosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[3-hydroxy-2-[[(12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-12,15,18,21,24,27-hexaenoyl]amino]tridecoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[2-[[(14Z,17Z,20Z,23Z,26Z,29Z)-dotriaconta-14,17,20,23,26,29-hexaenoyl]amino]-3-hydroxyundecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]pentacosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]pentacos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]nonadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyhenicosoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(19Z,22Z,25Z,28Z,31Z)-tetratriaconta-19,22,25,28,31-pentaenoyl]amino]non-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(4E,8E,12E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxyhenicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoyl]amino]pentadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(4E,8E)-2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]nonadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(4E,8E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxyhenicosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[2-[[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]amino]-3-hydroxyheptadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(E)-2-[[(17Z,20Z,23Z,26Z,29Z)-dotriaconta-17,20,23,26,29-pentaenoyl]amino]-3-hydroxyundec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(15Z,18Z,21Z,24Z,27Z)-triaconta-15,18,21,24,27-pentaenoyl]amino]tridec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
2-[[(E)-2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxyheptadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C48H88N2O6P+ (819.6379658000001)
phosphatidylcholine O-40:6
A glycerophosphocholine that is an alkyl,acyl-sn-glycero-3-phosphocholine in which the alkyl or acyl groups at positions 1 and 2 contain a total of 40 carbons and 6 double bonds.
1-octadecyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphocholine
A phosphatidylcholine O-40:6 in which the alkyl and the acyl groups at positions 1 and 2 are octadecyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively.
Hex1Cer(42:5)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(43:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved